Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 240.96
(-1.89%)
USD 240.96
(-1.89%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.8 Billion USD | 8.85% |
| 2022 | 1.65 Billion USD | 17.05% |
| 2021 | 1.41 Billion USD | 13.64% |
| 2020 | 1.24 Billion USD | 9.62% |
| 2019 | 1.13 Billion USD | 28.68% |
| 2018 | 881.34 Million USD | 52.84% |
| 2017 | 576.63 Million USD | 26.28% |
| 2016 | 456.61 Million USD | 43.57% |
| 2015 | 318.05 Million USD | -29.9% |
| 2014 | 453.72 Million USD | 223.73% |
| 2013 | 140.15 Million USD | -23.95% |
| 2012 | 184.28 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 491.91 Million USD | -9.33% |
| 2024 Q1 | 471.79 Million USD | 0.32% |
| 2024 Q2 | 542.53 Million USD | 15.0% |
| 2023 Q3 | 452.35 Million USD | -2.34% |
| 2023 Q4 | 470.26 Million USD | 3.96% |
| 2023 FY | 1.8 Billion USD | 8.85% |
| 2023 Q1 | 414.22 Million USD | -12.31% |
| 2023 Q2 | 463.21 Million USD | 11.83% |
| 2022 Q3 | 481.23 Million USD | 28.09% |
| 2022 Q2 | 375.69 Million USD | 15.83% |
| 2022 FY | 1.65 Billion USD | 17.05% |
| 2022 Q1 | 324.36 Million USD | -21.92% |
| 2022 Q4 | 472.38 Million USD | -1.84% |
| 2021 Q2 | 327.95 Million USD | -1.44% |
| 2021 Q4 | 415.43 Million USD | 23.4% |
| 2021 FY | 1.41 Billion USD | 13.64% |
| 2021 Q1 | 332.75 Million USD | -6.72% |
| 2021 Q3 | 336.64 Million USD | 2.65% |
| 2020 Q4 | 356.71 Million USD | 8.14% |
| 2020 FY | 1.24 Billion USD | 9.62% |
| 2020 Q3 | 329.84 Million USD | 38.68% |
| 2020 Q2 | 237.85 Million USD | -12.97% |
| 2020 Q1 | 273.29 Million USD | -20.4% |
| 2019 Q1 | 218.69 Million USD | -9.26% |
| 2019 FY | 1.13 Billion USD | 28.68% |
| 2019 Q4 | 343.34 Million USD | 21.04% |
| 2019 Q3 | 283.66 Million USD | 5.97% |
| 2019 Q2 | 267.69 Million USD | 22.41% |
| 2018 Q2 | 199.48 Million USD | 18.06% |
| 2018 Q1 | 168.96 Million USD | -8.36% |
| 2018 FY | 881.34 Million USD | 52.84% |
| 2018 Q4 | 241.01 Million USD | -4.95% |
| 2018 Q3 | 253.56 Million USD | 27.11% |
| 2017 Q4 | 184.38 Million USD | 28.65% |
| 2017 FY | 576.63 Million USD | 26.28% |
| 2017 Q3 | 143.32 Million USD | 4.67% |
| 2017 Q2 | 136.92 Million USD | 6.66% |
| 2017 Q1 | 128.37 Million USD | -3.03% |
| 2016 Q1 | 112.13 Million USD | 12.26% |
| 2016 Q2 | 100.23 Million USD | -10.61% |
| 2016 Q4 | 132.38 Million USD | 10.67% |
| 2016 Q3 | 119.62 Million USD | 19.35% |
| 2016 FY | 456.61 Million USD | 43.57% |
| 2015 Q1 | 70.75 Million USD | 3.63% |
| 2015 FY | 318.05 Million USD | -29.9% |
| 2015 Q4 | 99.88 Million USD | 17.9% |
| 2015 Q3 | 84.72 Million USD | 3.76% |
| 2015 Q2 | 81.65 Million USD | 15.4% |
| 2014 Q4 | 68.27 Million USD | 22.7% |
| 2014 Q3 | 55.64 Million USD | 6.24% |
| 2014 Q2 | 52.37 Million USD | -81.12% |
| 2014 Q1 | 277.42 Million USD | 585.53% |
| 2014 FY | 453.72 Million USD | 223.73% |
| 2013 FY | 140.15 Million USD | -23.95% |
| 2013 Q4 | 40.46 Million USD | -1.86% |
| 2013 Q1 | 28.44 Million USD | -65.09% |
| 2013 Q2 | 30 Million USD | 5.52% |
| 2013 Q3 | 41.23 Million USD | 37.41% |
| 2012 FY | 184.28 Million USD | 0.0% |
| 2012 Q4 | 81.47 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 95.566% |
| uniQure N.V. | 285.08 Million USD | -531.41% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -14726.299% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -340.322% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -320.918% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -552.922% |
| bluebird bio, Inc. | 240.23 Million USD | -649.301% |
| Blueprint Medicines Corporation | 722.86 Million USD | -149.019% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1163.529% |
| Imunon, Inc. | 21.03 Million USD | -8459.316% |
| Adicet Bio, Inc. | 152.03 Million USD | -1083.955% |
| Dynavax Technologies Corporation | 219.14 Million USD | -721.402% |
| Editas Medicine, Inc. | 247.3 Million USD | -627.874% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1391.883% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -299.133% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 12.32% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -65.236% |
| Myriad Genetics, Inc. | 600.1 Million USD | -199.96% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -12.75% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -32.278% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -240.269% |
| Verastem, Inc. | 92.08 Million USD | -1854.803% |
| Waters Corporation | 943.51 Million USD | -90.782% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 62.302% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 82.445% |
| Biogen Inc. | 5.2 Billion USD | 65.416% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1685.297% |
| Perrigo Company plc | 1.52 Billion USD | -17.767% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3929.957% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -562.038% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -3611.313% |
| Geron Corporation | 70.44 Million USD | -2455.417% |
| Illumina, Inc. | 3.81 Billion USD | 52.791% |
| Homology Medicines, Inc. | 9.87 Million USD | -18128.466% |
| Nektar Therapeutics | 190.9 Million USD | -842.919% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -12841.103% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -3.08% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -687.153% |
| Evolus, Inc. | 189.75 Million USD | -848.604% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 36.061% |
| FibroGen, Inc. | 398.11 Million USD | -352.148% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 14.891% |
| OPKO Health, Inc. | 574.68 Million USD | -213.225% |
| Exelixis, Inc. | 1.58 Billion USD | -13.441% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -3128.462% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -226.355% |
| Zoetis Inc. | 2.76 Billion USD | 34.898% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -277.878% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -4497.505% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -130.899% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -388.335% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -501.387% |
| Insmed Incorporated | 949.26 Million USD | -89.628% |
| TG Therapeutics, Inc. | 198.47 Million USD | -806.946% |
| Incyte Corporation | 1.19 Billion USD | -51.203% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -72.42% |